Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Intra-Cellular Therapies (Nasdaq: ITCI) has announced that its CEO, Sharon Mates, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 11:45 a.m. ET. This event will be available as a live and archived webcast, accessible via the Events & Presentations section of their website. Attendees are advised to log in 5-10 minutes early to register and install any necessary software.

Founded on Nobel prize-winning research, Intra-Cellular Therapies focuses on developing therapeutics for complex psychiatric and neurologic diseases. Their innovative approach targets the inner workings of cells to create effective treatments. For more details, visit www.intracellulartherapies.com.

News Market Reaction – ITCI

-0.63%

-0.63% Session move

In the trading session that priced this news, ITCI declined 0.63%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 at 11:45 a.m. ET.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases. For more information, please visit www.intracellulartherapies.com.

Contact:

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
cradinovic@burnsmc.com
212-213-0006

FAQ

When is Intra-Cellular Therapies scheduled to present at the Needham Virtual Healthcare Conference?

Intra-Cellular Therapies is scheduled to present on April 18, 2023, at 11:45 a.m. ET.

How can I access the webcast for Intra-Cellular Therapies' presentation?

The live and archived webcast can be accessed in the Events & Presentations section of Intra-Cellular Therapies' website.

What is the focus of Intra-Cellular Therapies?

Intra-Cellular Therapies focuses on developing therapeutics for central nervous system disorders, particularly complex psychiatric and neurologic diseases.

Who is presenting for Intra-Cellular Therapies at the conference?

Sharon Mates, Ph.D., the CEO and Chairman of Intra-Cellular Therapies, will be presenting.

What is the stock symbol for Intra-Cellular Therapies?

The stock symbol for Intra-Cellular Therapies is ITCI.